Out of stock
Medicine Overview of Clexane 6000 anti-XaIU 60mg/0.6ml Injection
বাংলা
English
Indication
Myocardial infarction, Unstable angina, Venous thromboembolism, Deep vein thrombosis
Administration
Low body weight (<45 kg for women or <57 kg for men): Increased exposure has been observed with prophylactic (non-weight adjusted) dosage; carefully monitor for sign/symptoms of bleeding
Administer deep SC alternating right and left anterior and posterior abdominal walls into skin fold held between thumb and forefinger
Use of tuberculin syringe (or equivalent) is recommended to assure appropriate measurement of dose
For IV administration, may administer in IV line with 0.9% NaCl or D5W
Adult Dose
Deep Vein Thrombosis (Prophylaxis) Prevent the occurrence of pulmonary embolism in patients at risk for thromboembolic complications who are undergoing abdominal surgery or hip or knee replacement surgery, as well as in medical patients with severely restricted mobility during acute illness Abdominal surgery 40 mg SC qDay; initiate 2 hr preoperatively Knee or hip replacement surgery 30 mg SC q12hr; initiate therapy 12-24 hr postoperatively and continued for 10 days or up to 35 days postoperatively or until risk of DVT has been significantly reduced or patient is on anticoagulant therapy For hip replacement surgery, may consider administering 40 mg...
... Show moreRenal Dose
Renal impairment
Severe (CrCl 75 years): No initial bolus; maintenance of 1 mg/kg SC qDay
Contraindication
Hyper-sensitivity to either Enoxaparin, heparin or other low molecular weight heparins; major clotting disorders like history of thrombocytopenia, active gastro-intestinal ulcer or organic lesion likely to bleed, recent haemorrhagic vascular cerebral stroke. Although rare, cutaneous or systemic allergic reactions may occur.
Mode of Action
Enoxaparin is a low molecular weight heparin w/ anticoagulant properties. It acts by enhancing the inhibition rate of activated clotting factors including thrombin and factor Xa through its action on antithrombin III.
Precaution
Enoxaparin injection should not be administered by intramuscular route. Enoxaparin should be used with caution in conditions with increased potential for bleeding, such as impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy, recent neuro or opthalmologic surgery and low weight patients. It is recommended that the platelet count be measured befored the initiation of the treatment and regularly thereafter during treatment.
Lactation: Excretion in milk unknown; not recommended
Side Effect
1-10%
Hemorrhage (1-4%),Elevation of serum aminotransferases (6%),Fever (5-8%),Local site reactions (2-5%),Thrombocytopenia (3%),Nausea (3%),Anemia (2%),Ecchymosis (3%)
<1%
Atrial fibrillation,Heart failure,Pulmonary edema,Pneumonia
Potentially Fatal: Haemorrhagic complications.
Pregnancy Category Note
Pregnancy Human data from a retrospective cohort study, suggest that enoxaparin does not increase risk of major developmental abnormalities Pregnancy alone confers increased risk for thromboembolism that is higher for women with thromboembolic disease and certain high risk pregnancy conditions; while not adequately studied, pregnant women with mechanical prosthetic heart valves may be at even higher risk for thrombosis; pregnant women with thromboembolic disease, including those with mechanical prosthetic heart valves and those with inherited or acquired thrombophilias, have an increased risk of other maternal complications and fetal loss regardless of type of anticoagulant used All patients receiving anticoagulants, including...
... Show moreInteraction
Increased risk of bleeding w/ anticoagulants, platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs, sulfinpyrazone). May increase bleeding w/ vit E.
